Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin

Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Study ID
NCT07502001
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 45 Years
Healthy Volunteers
Accepted

Interventions

  • Acetaminophen — DRUG
    Single dose; Administered orally
  • Metformin — DRUG
    Single dose; Administered orally
  • Warfarin — DRUG
    Single dose; Administered orally
  • Atorvastatin — DRUG
    Single dose; Administered orally
  • Digoxin — DRUG
    Single dose; Administered orally
  • HDM1005 injection — DRUG
    Subcutaneous injection QW

Study Details

The purpose of this study is to characterize the Influence of HDM1005 on gastric emptying and drug-drug interaction of HDM1005 and metformin, atorvastatin, warfarin, and digoxin in overweight/obese adult subjects.

Key Dates

First listed
Mar 30, 2026
Start date
Apr 8, 2026
Status verified
Mar 2026
Primary completion
Dec 1, 2026
Completion
Jun 2, 2027

Study Design

Enrollment
42 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment group

Primary Outcome Measure

Area Under the Concentration Time Curve From Time Zero to ∞ [ AUC(0- ∞)] [ Time Frame: Up to Day 115 ]

Related Studies